• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy　― An Observational Pharmacy Claims Database Study ―
【24h】

Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy　― An Observational Pharmacy Claims Database Study ―

机译：日本血脂异常患者使用依他汀-依泽替米贝作为单独的药物组合降脂治疗的药物依从性/持久性和人口统计学－观察性药房索赔数据库研究―

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: This study aimed to identify potential predictors of medication adherence and persistence with statin-ezetimibe combinational lipid-lowering therapy (LLT) as a separate pill combination in a real-world setting in Japan. Methods?and?Results: Patients newly switched to statin-ezetimibe combinational LLT from statin monotherapy were identified within a Japanese national pharmacy claims database during January 2015 to April 2018. Adherence and persistence were measured by the proportion of days covered (PDC), time to treatment discontinuation and persistence rate at 1 year. A stepwise multivariate logistic regression model and Cox proportional hazards regression model were used to explore potential predictors associated with adherence and persistence, respectively. Among 6,921 patients, 71.9% were adherent (PDC ≥80%), and 83.6% were persistent at 1 year after initiation. Patients aged ≤54 years and ≥75 years were prone to be more non-adherent. Secondary prevention was associated with better adherence and longer persistence. Concomitant use of medications for depression/anxiety was associated with shorter persistence, whereas use of antihypertensive drugs was associated with better adherence and persistence. Conclusions: Age, concomitant use of certain classes of medications (or the existence of these diseases) and secondary prevention were associated with adherence and persistence of statin-ezetimibe combinational LLT. Given that dyslipidemia is a chronic disease requiring life-long control, active interventions are required for patients with poor adherence and persistence.
机译：背景：本研究旨在确定在现实世界中，他汀-依泽替米贝联合降脂治疗（LLT）作为单独的药丸组合，可能会导致药物依从性和持久性的预测指标。方法和结果：在2015年1月至2018年4月的日本国家药房索赔数据库中，确定了从他汀单药新改用他汀-依泽替米贝联合LLT的患者。通过覆盖天数（PDC），时间来衡量患者的依从性和持久性终止治疗和1年的持续率。逐步多元logistic回归模型和Cox比例风险回归模型分别用于探索与依从性和持久性相关的潜在预测因素。在6,921例患者中，有71.9％的患者是依从性的（PDC≥80％），有83.6％的患者在发病后1年持续。 ≤54岁和≥75岁的患者更倾向于不依从。二级预防与更好的依从性和更长的持久性相关。伴随使用药物治疗抑郁症/焦虑症与持续时间短有关，而使用降压药与改善依从性和持久性有关。结论：年龄，同时使用某些类药物（或这些疾病的存在）和二级预防与他汀-依泽替米贝联合LLT的依从性和持续性有关。由于血脂异常是需要终生控制的慢性疾病，因此对于依从性和持久性较差的患者，需要积极干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号